Justin P O Lindemann

9PUBLICATIONS
98CO-AUTHORS
Predictive and prognostic markersMolecular targetsCarbon capture engineering (excl. sequestration)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Feb 02, 2026
Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study.

John F R Robertson, Teimuraz Gogitidze, Zaza Katashvili

|Jan 21, 2026
Open-Label Study Assessing Relative and Absolute Bioavailability of Oral Camizestrant Formulations and Food Effects in Healthy Postmenopausal Women.

Andy Sykes, Helena Engman, Nigel Taylor

|Aug 11, 2025
Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2- Advanced Breast Cancer: Results from SERENA-1.

Richard D Baird, Begoña Bermejo de Las Heras, Manuel Ruiz-Borrego

|Sep 19, 2023
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.

Mandy Lawson, Natalie Cureton, Susana Ros

|Apr 17, 2021
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer.

Lillian M Smyth, Gerald Batist, Funda Meric-Bernstam

|Jun 14, 2020
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant Cancers.

Timothy A Yap, Rebecca Kristeleit, Vasiliki Michalarea

Pageof 2

Frequent Collaborators

4 joint publications

S Y Amy Cheung

3 joint publications

Alastair Mathewson

3 joint publications

Teresa Klinowska

3 joint publications

Christopher J Morrow